Using a Single Dose of rFVIIa for Bleeding in Hemophilia A
Author Information
Author(s): Delfina Almagro, O. Agramonte, D. Castillo, Y. Zamora, J. M. Ballester
Primary Institution: Institute of Hematology and Immunology, La Habana, Cuba
Hypothesis
Can a single higher dose of recombinant activated factor VII (rFVIIa) effectively manage mild-to-moderate bleeding episodes in hemophilia A patients with inhibitors?
Conclusion
A single dose of rFVIIa effectively stopped bleeding in 59% of children and 37.5% of adults with hemophilia A and inhibitors.
Supporting Evidence
- A single dose of rFVIIa 180 μg kg−1 stopped bleeding in 59% of children.
- Haemostasis was achieved after a second dose in 37% of cases.
- 37.5% of adults achieved a good response with the initial dose.
Takeaway
Doctors gave a special medicine to kids and adults with a bleeding problem, and it worked really well for most of them.
Methodology
Patients with mild-to-moderate bleeds received a single bolus dose of rFVIIa, and their responses were evaluated.
Potential Biases
No conflicts of interest were reported by the authors.
Limitations
The study was small and used lower doses of rFVIIa than those shown to be effective in other studies.
Participant Demographics
Five children up to 14 years and three adults were included in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website